Form 4: Nektar Therapeutics Chief Legal Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Mark Andrew Wilson, Chief Legal Officer of Nektar Therapeutics, sold 5,651 shares of common stock on August 19, 2024, to cover tax withholding obligations related to vesting RSUs.
Summary
- On August 19, 2024, Mark Andrew Wilson, the Chief Legal Officer of Nektar Therapeutics, sold 5,651 shares of the company's common stock.
- The sale was executed to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- The shares were sold at a weighted average price of $1.28, with individual transactions ranging from $1.24 to $1.32.
- Following the transaction, Wilson still beneficially owns 225,263 shares, including 6,607 shares held in the Issuer's ESPP plan.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to a stock sale for tax purposes, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. This transaction is related to tax obligations and is not necessarily indicative of the officer's sentiment about the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of stock sale transaction |
| 08/20/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.